Skip to main content

A Randomized Open Label Phase 2 Study of Denintuzumab mafodotin (SGN -CD19A)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Seattle Genetics, Inc

Start Date

May 23, 2016

End Date

February 18, 2019
 

Administered By

Duke Cancer Institute

Awarded By

Seattle Genetics, Inc

Start Date

May 23, 2016

End Date

February 18, 2019